Literature DB >> 21164283

Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.

Sanjay Mukhopadhyay1, Anna-Luise A Katzenstein.   

Abstract

The availability of targeted therapies has created a need for precise subtyping of non-small cell lung carcinomas (NSCLCs). The aim of this study was to assess the utility of immunohistochemical markers in subtyping poorly differentiated NSCLC and to compare the results of immunohistochemical staining on biopsies with the corresponding resections. Thirty-nine cases of NSCLC that could not be further classified on biopsy and had subsequent resection specimens were identified. Classification of the tumor was based on the resection specimen using the World Health Organization criteria. All biopsies and resections were stained with CK7, TTF-1, napsin A (novel aspartic proteinase of the pepsin family), p63, CK5/6, and 34βE12. The specimens included 20 adenocarcinomas (ACs), 15 squamous cell carcinomas (SCCs), and 4 large-cell carcinomas (LCCs). TTF-1 was positive in biopsies from 16 of 20 ACs, 2 of 4 LCCs, and none of the SCCs. p63 was positive in all 15 SCCs, 2 of 20 ACs (both were also positive for TTF-1 and napsin A), and none of the LCCs. CK5/6 was positive in 11 of 15 SCCs (all p63 positive) but none of the ACs or LCCs. Napsin A stained 11 of 19 ACs (all TTF-1 positive) but none of the other tumors. Staining for CK7 was present in 19 of 19 ACs and 9 of 15 SCCs. 34βE12 stained both SCCs (15 of 15) and ACs (12 of 20). The combination of TTF-1, napsin A, p63, and CK5/6 allowed an accurate classification of 30 of39 (77%) cases. Of 232 pairs of slides (biopsy and resection) stained with immunohistochemical markers, 12 (5%) showed discrepancies in immunohistochemical staining between biopsies and their corresponding resections. Immunohistochemical staining using a combination of TTF-1, napsin A, p63, and CK5/6 allows subclassification of poorly differentiated NSCLCs on small lung biopsies in most cases. Discrepancies in immunohistochemical staining between biopsies and resections are uncommon.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21164283     DOI: 10.1097/PAS.0b013e3182036d05

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  70 in total

1.  STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma.

Authors:  Yukihiro Otaka; Susumu Rokudai; Kyoichi Kaira; Michiru Fujieda; Ikuko Horikoshi; Reika Iwakawa-Kawabata; Shinji Yoshiyama; Takehiko Yokobori; Yoichi Ohtaki; Kimihiro Shimizu; Tetsunari Oyama; Jun'ichi Tamura; Carol Prives; Masahiko Nishiyama
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

2.  The evolving role of the pathologist in the management of lung cancer.

Authors:  Adi F Gazdar
Journal:  Lung Cancer Manag       Date:  2012

Review 3.  The pivotal role of pathology in the management of lung cancer.

Authors:  Morgan R Davidson; Adi F Gazdar; Belinda E Clarke
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 4.  Liver metastases.

Authors:  Diamantis I Tsilimigras; Pnina Brodt; Pierre-Alain Clavien; Ruth J Muschel; Michael I D'Angelica; Itaru Endo; Rowan W Parks; Majella Doyle; Eduardo de Santibañes; Timothy M Pawlik
Journal:  Nat Rev Dis Primers       Date:  2021-04-15       Impact factor: 52.329

5.  A panel of four immunohistochemical markers (CK7, CK20, TTF-1, and p63) allows accurate diagnosis of primary and metastatic lung carcinoma on biopsy specimens.

Authors:  Diana Montezuma; Rosa Azevedo; Paula Lopes; Renata Vieira; Ana Luísa Cunha; Rui Henrique
Journal:  Virchows Arch       Date:  2013-10-15       Impact factor: 4.064

6.  Diagnosing lung carcinomas with optical coherence tomography.

Authors:  Lida P Hariri; Mari Mino-Kenudson; Michael Lanuti; Alyssa J Miller; Eugene J Mark; Melissa J Suter
Journal:  Ann Am Thorac Soc       Date:  2015-02

7.  Seeing beyond the bronchoscope to increase the diagnostic yield of bronchoscopic biopsy.

Authors:  Lida P Hariri; Martin Villiger; Matthew B Applegate; Mari Mino-Kenudson; Eugene J Mark; Brett E Bouma; Melissa J Suter
Journal:  Am J Respir Crit Care Med       Date:  2013-01-15       Impact factor: 21.405

8.  Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens.

Authors:  Mark Kriegsmann; Rita Casadonte; Jörg Kriegsmann; Hendrik Dienemann; Peter Schirmacher; Jan Hendrik Kobarg; Kristina Schwamborn; Albrecht Stenzinger; Arne Warth; Wilko Weichert
Journal:  Mol Cell Proteomics       Date:  2016-07-29       Impact factor: 5.911

Review 9.  [Non-small cell lung cancer. New biomarkers for diagnostics and therapy].

Authors:  G Kayser
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

10.  The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer.

Authors:  Ming-Hui Ao; Hui Zhang; Lynne Sakowski; Rajni Sharma; Peter B Illei; Edward Gabrielson; Frederic Askin; Qing Kay Li
Journal:  Hum Pathol       Date:  2014-01-25       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.